EVRY, FRANCE, March 10^th , 2025 – AGS Therapeutics, a preclinical-stage biotech company pioneering Microalgae Extracellular Vesicles (MEVs) as a novel, universal delivery system, today announced the appointment of Dr. Alexander Suma as an Independent Director to its Board. Dr. Suma brings extensive expertise in entrepreneurship, capital raising, and sustainable innovation, further reinforcing AGS Therapeutics’ leadership as it advances its breakthrough MEV technology.

‍

Dr. Suma is a distinguished entrepreneur, business leader, and innovator with over fifteen years of experience in renewable energy, sustainability, clean-tech, and climate-tech. As the founder and CEO of Nexuma, he specializes in accelerating the commercialization of climate technology startups, leveraging his expertise in growth strategy, investment due diligence, and technology development. His track record includes leading multiple companies from inception to international success, securing significant funding, and developing sustainable solutions that have earned global recognition.

‍

A Leader in Sustainability and Capital Strategy

‍

As a Board member, Dr. Suma will play a pivotal role in supporting AGS Therapeutics’ fundraising efforts, drawing upon his extensive experience in securing capital for high growth ventures. His deep knowledge of sustainable innovations and lean-tech ecosystems will further contribute to AGS’s commitment to environmentally responsible biotechnology and long-term capital strategy.

‍

“We are excited to welcome Alexander to our Board of Directors,” said Manuel Vega, CEO of AGS Therapeutics. “His entrepreneurial mindset, financial acumen, and deep understanding of sustainability will be invaluable as we continue to develop our MEV technology. Alexander’s ability to bridge innovation and investment will help propel AGS forward. Coming from an industry distinct from biotech-pharma yet similarly defined by game-changing breakthroughs, he brings transversal, independent insights. His success is built on unconventional paths, personal vision, and pragmatic execution—qualities that align perfectly with AGS’s pioneering spirit. His guidance will be instrumental in helping AGS forge its own path rather than merely following existing models.”

‍

Dr. Suma expressed his enthusiasm for joining AGS Therapeutics: “I am honored to join AGS Therapeutics at such an exciting stage in its journey. The company’s pioneering work in Microalgae Extracellular Vesicles presents a transformative opportunity for the biotech industry. I look forward to leveraging my network and experience in capital raising and sustainable technology to help AGS realize its ambitious goals and drive meaningful impact in healthcare.”

‍

About AGS Therapeutics

‍

AGS Therapeutics, based in Paris and at Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative therapeutics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS's programs include AGS-1010 and AGS-2010. AGS-1010 carries an anti-angiogenesis agent loaded into MEVs and is intended for the treatment of wAMD. AGS-1010 can be delivered to the back of the eye-by-eye drops (drop instillation), which differentiates it from all products (in the market or in development, for the treatment of wAMD). AGS-2010 carries a modulator of TLR-9 activity, loaded into MEVs, and is intended for the treatment of IBD. AGS-2010 is delivered directly to the intestinal epithelial cells following the oral administration of the loaded MEVs. AGS-2010 differentiates from current treatments of IBD by the highly targeted delivery to the site of action (the intestine) through the intestinal lumen, thus avoiding the systemic route. AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D at AGS and for companies partnering with AGS. AGS’s MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’s MEVs are easy to manufacture in large quantities with processes that are sustainable, straightforward (simple), scalable, resource-effective, and cost-effective. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape and improve the lives of patients across the globe. For more information, visit www.ags-tx.com and www.ags-m.com.

‍

Forward-Looking Statement

‍

This announcement may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on the future, they are subject to risks and uncertainties that could cause actual results to differ materially. Readers cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this communication.

‍

Contacts

‍

Marie-Hélène Leopold | AGS Therapeutics | +33 (0)6 07 16 55 01 | mhl@ags-tx.com

Ana Vega | Markets & Listing | +33 (0)6 88 57 05 77 | av@markets-listing.com

‍